ARDX Ardelyx, Inc.
Legal ·
Yarborough v. Ardelyx named the company and executives Michael Raab, Susan Rodriguez, Laura Williams and Elizabeth Grammer. The First Circuit appeal was dismissed on March 26, 2026.
Ardelyx received the funds on June 29, 2026 under its 2022 loan and security agreement. The loan bears interest of 4.55% plus the greater of 1-month SOFR or 3.5%, with interest-only payments until July 1, 2030.
Ardelyx drew a $50.0 million Term F Loan from SLR Investment Corp. on June 29, 2026. The loan matures July 1, 2030 at 4.55% plus the greater of 1-month SOFR or 3.5%, and in a default the agent can reach the company's cash.
Jefferies LLC is the sales agent for up to $100,000,000 of common stock. A second Jefferies program, dated January 18, 2023, may still sell up to approximately $80.0 million.
Ardelyx is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative medicines for unmet medical needs. It markets two therapies from tenapanor, a minimally absorbed, first-in-class, oral small molecule sodium/hydrogen exchanger (NHE3) inhibitor that Ardelyx discovered and developed. IBSRELA is approved in the U.S. for adults with irritable bowel syndrome with constipation (IBS-C), and the company has initiated a Phase 3 trial of tenapanor in adults with chronic idiopathic constipation to expand that population. XPHOZAH is approved in the U.S. to reduce serum phosphorus in adults with chronic kidney disease on dialysis, as add-on therapy for patients with an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. The company is also developing a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. The text says Ardelyx has incurred losses in each year since its inception in October 2007.
| Product or program | What it is | Stage |
|---|---|---|
| IBSRELA | First-in-class NHE3 inhibitor for IBS-C in adults | approved in the U.S. |
| XPHOZAH | Add-on therapy to reduce serum phosphorus in adults on dialysis | approved in the U.S. |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $71.5 million | $52.3 million |
| Net income (loss) | -$61.6 million | -$39.1 million |
| Cash from operations | -$42.5 million | -$44.8 million |
| Cash and equivalents | $68.0 million | $64.9 million |
| Short-term investments | $196.7 million | $185.2 million |
Our latest story on this, dated Nov 3, 2025: "Ardelyx files automatic shelf with $100,000,000 ATM sales agreement supplement". The story links the filing or release it is based on. Read the story.
Ardelyx, Inc. trades under the ticker ARDX on NASDAQ.
Ardelyx, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:41X; LS:A116X0; LSX:A116X0.
The SEC Central Index Key (CIK) for Ardelyx, Inc. is 1437402. Its filings are on SEC EDGAR.
249,187,572 shares as of 2026-07-30, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Ardelyx, Inc. under United States.
Our directory classifies Ardelyx, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Ardelyx, Inc. is US0396971071.
aibio.space lists Ardelyx, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Ardelyx is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative medicines for unmet medical needs. It markets two therapies from tenapanor, a minimally absorbed, first-in-class, oral small molecule sodium/hydrogen exchanger (NHE3) inhibitor that Ardelyx discovered and developed.
IBSRELA: First-in-class NHE3 inhibitor for IBS-C in adults Stage: approved in the U.S..
XPHOZAH: Add-on therapy to reduce serum phosphorus in adults on dialysis Stage: approved in the U.S..
Ardelyx, Inc. reported a net loss of $61.6 million for the fiscal year ended Dec 31, 2025, and used $42.5 million of cash in operations, per its annual report to the SEC.
$71.5 million in the fiscal year ended Dec 31, 2025, per its annual report.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio